With their announcement came the birth of modern biotechnology. Based on their work, in 1982, the first genetically engineered product, human insulin, was brought to market. In fact, we are experiencing a profound revolution in the field of health research - a revolution, which may lead soon to our understanding of the molecular basis of human biology and disease. Eventually, our understanding of our human genes will lead to health strategies to avoid disease, not fight disease. The impact of the genomic revolution can be enormous here in Canada.
Biotechnology cuts across many sectors of industry.
The Government of Canada consistently has identified the development of a strong and vibrant biotechnology sector as a key priority area for its attention. Clearly, biotechnology can contribute to stemming the brain drain, creating employment and ultimately improving the personal and economic health of Canadians. However, amongst the Coalition s members, there is a growing discomfort with the pace at which Canadians researchers are able to compete in the biotechnology development race. Just as Canada has not kept pace in e-commerce, so too, the window of opportunity to compete in the biotech arena in a significant manner is narrow and swiftly closing. CBHR remains convinced that the development and implementation of solid comprehensive national policy for the development of a vigorous biotechnology industry in Canada is essential to the health of Canadians and to our economic well being in during the next few decades.